An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world setting in Japan

Trial Identifier:	D8850R00032
Sponsor:	AstraZeneca
NCTID::	NCT06156982
Start Date:	December 2023
Primary Completion Date:	January 2024
Study Completion Date:	January 2024
Condition:	COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Japan	Osaka, Japan

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.